Given that as many of 60% of people with a clinical presentation consistent with NF2-SWN may have mosaic disease, clinicians should be aware of the need to test blood and ideally ≥ 2 potentially associated tumours (i.e. schwannoma, meningioma, ependymoma) from distinct regions of the nervous system. The gene discussed is NF2; the disease is schwannoma.